Tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AssigneeLudwig Institute for Cancer Research
InventorsVincent Brichard, Aline Van Pel, Catia Traversari, Thomas Wolfel, Thierry Boon-Falleur, Etienne De Plaen
Life of this patent
Estimating the term…
Abstract
The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
Claims2
An isolated tumor rejection antigen precursor molecule which is not a tyrosinase, and which comprises an amino acid sequence corresponding to a peptide which forms a complex with HLA-A2 molecule, said isolated tumor rejection antigen precursor molecule having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.